11 May 2017 | News
The certification will help GNH India trade freely with Kenya.
GNH India, a leading pharmaceutical distributor has cleared the Kenyan Pharmacy and Poisons Board audit thereby clearing the path for it to export scheduled drugs to Kenya. It has become the first Indian company to clear such audit.
The certification will help GNH India trade freely with Kenya. The company will export the first shipment of lifesaving drugs to Kenya shortly and is looking to establish long lasting business relations with the country. The country, which has been facing a dearth of many lifesaving drugs in recent times will be benefited by this development.
GNH India, exports to more than 180 countries and has 135,000 product lines to choose from which makes this company one of the leading businesses in the $12.5 billion Indian pharmaceutical export industry. This recent development has extended their reach into Kenya which has added to the long list of countries they already export medicines to.
The Pharmacy and Poisons Board is the Drug Regulatory Authority established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya, and is responsible for regulating the Practice of Pharmacy and the Manufacture and Trade in drugs and poisons in Kenya.
Commenting on this, Dr Piyush Gupta, Associate Director, GNH India said, “GNH India has always believed that everyone should have access to proper healthcare and medicines, and we strive to deliver the same to the people irrespective of the global boundaries"
"We always adhere to appropriate practices and maintain quality standards while servicing our clients, and being certified by The Pharmacy and Poisons Board, Kenya authenticates the measures taken by us for the exports of medicines. It gives us tremendous pleasure to be the first Indian specialized wholesaler to clear the audit by any foreign body, and we look forward to many more opportunities.”
GNH India was audited in compliance to Good Distribution Practices (GDP), the criteria of the audit are based on World Health Organization’s (WHO) Good Distribution Practices for Pharmaceutical products and European Union’s guidelines on GDP of medical products for human use.